Xamoterol: Difference between revisions
m Protected "Xamoterol": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
No edit summary |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 25: | Line 25: | ||
}} | }} | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
'''Xamoterol''' is a [[cardiac stimulant]]. It works by binding to the [[β1 adrenergic receptor]]<ref name=Rang163> {{cite book |author=Rang, H. P. |title=Pharmacology |publisher=Churchill Livingstone |location=Edinburgh |year=2003 |pages= |isbn=0-443-07145-4 |oclc= |doi=}} Page 163</ref> | '''Xamoterol''' is a [[cardiac stimulant]]. It works by binding to the [[β1 adrenergic receptor]]. It is a 3rd generation adrenergic beta receptor partial agonist. It provides cardiac stimulation at rest but it acts as a blocker during exercise. <ref name=Rang163>{{cite book |author=Rang, H. P. |title=Pharmacology |publisher=Churchill Livingstone |location=Edinburgh |year=2003 |pages= |isbn=0-443-07145-4 |oclc= |doi=}} Page 163</ref> | ||
==References== | |||
{{reflist|2}} | |||
{{Cardiac stimulants excluding cardiac glycosides }} | {{Cardiac stimulants excluding cardiac glycosides }} | ||
[[Category: | [[Category:Beta-adrenergic agonists]] | ||
[[Category: | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drug]] | |||
[[Category: | |||
Latest revision as of 20:40, 24 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C16H25N3O5 |
| Molar mass | 339.387 g/mol |
|
WikiDoc Resources for Xamoterol |
|
Articles |
|---|
|
Most recent articles on Xamoterol |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Xamoterol at Clinical Trials.gov Clinical Trials on Xamoterol at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Xamoterol
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Xamoterol Discussion groups on Xamoterol Directions to Hospitals Treating Xamoterol Risk calculators and risk factors for Xamoterol
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Xamoterol |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Xamoterol is a cardiac stimulant. It works by binding to the β1 adrenergic receptor. It is a 3rd generation adrenergic beta receptor partial agonist. It provides cardiac stimulation at rest but it acts as a blocker during exercise. [1]
References
- ↑ Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. Page 163
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Beta-adrenergic agonists
- Cardiovascular Drugs
- Drug